BMY-20014

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameBMY-20014
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 antagonistsVoltage-gated calcium channel blockers
TargetsVoltage-gated calcium channelAdrenergic receptors alpha-2
Therapy Area/IndicationsMyocardial Ischemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
Active IndicationsN/A
Inactive IndicationsMyocardial Ischemia

Other Information

ATC CodeN/A
Related LinksN/A